Biogen Idec (NASDAQ:BIIB) traded today at a new 52-week high of $179.61. So far today approximately 813,000 shares have been exchanged, as compared to an average 30-day volume of 1.2 million shares.
In the past 52 weeks, Biogen Idec share prices have been bracketed by a low of $121.84 and a high of $179.61 and are now at $179.49, 47% above that low price. In the last five trading sessions, the 50-day moving average (MA) has climbed 1.2% while the 200-day MA has risen 0.4%.
Biogen Idec Inc. develops, manufactures, and commercializes therapies, focusing on neurology, oncology, and immunology. The Company's products addresses diseases such as multiple sclerosis, non-Hodgkin's lymphoma, rheumatoid arthritis, crohn's disease, and psoriasis.
Based on a current price of $179.49, Biogen Idec is currently 1.6% above its average consensus analyst price target of $176.55. The stock should discover initial support at its 50-day moving average (MA) of $163.12 and subsequent support at its 200-day MA of $150.39.